Can I Take St. John's Wort With Dayvigo (Lemborexant)?

The Short Answer: St. John's Wort and Dayvigo Should Not Be Combined

The Dayvigo (lemborexant) FDA prescribing information explicitly states that co-administration with strong or moderate CYP3A4 inducers is contraindicated. St. John's Wort (Hypericum perforatum) is one of the best-characterized strong CYP3A4 inducers in clinical pharmacy. Taking both together is not a theoretical concern. It is a documented drug-supplement interaction with real consequences for your sleep and your health.

Why Women Are Especially Likely to Be Using Both

Women are the primary users of both prescription sleep aids and herbal supplements for mood and sleep. Insomnia affects women at higher rates than men across the adult lifespan, with prevalence reaching 40-60% during perimenopause and early postmenopause, largely driven by nocturnal hot flashes and estrogen withdrawal effects on sleep architecture. At the same time, St. John's Wort is one of the most widely purchased herbal supplements in the United States, used by women for low mood, mild anxiety, and sleep support, often without disclosing it to their prescriber.

The overlap is predictable: a perimenopausal woman starts Dayvigo for sleep maintenance insomnia, continues St. John's Wort she has been taking for mood, and neither her pharmacist nor her prescriber catches the interaction because she did not think an herb counted as a "real" medication.

What Lemborexant Does in Your Body

Lemborexant is a dual orexin receptor antagonist (DORA). It blocks orexin-1 and orexin-2 receptors in the brain, quieting the wake-promoting signals that keep you alert. The SUNRISE-1 and SUNRISE-2 trials showed statistically significant improvements in sleep onset latency and sleep maintenance compared with placebo in adults with chronic insomnia disorder, and SUNRISE-2 included a head-to-head comparison with zolpidem extended-release.

Lemborexant is primarily metabolized by CYP3A4, with minor contributions from CYP3A5. That single metabolic pathway is its Achilles heel for enzyme-inducing supplements.

How CYP3A4 Induction Destroys the Interaction: The Mechanism

CYP3A4 is a liver and intestinal enzyme responsible for metabolizing roughly 50% of all prescription drugs. When an inducer like St. John's Wort is present, the body makes more of this enzyme. More enzyme means faster breakdown of lemborexant. Faster breakdown means lower blood concentrations. Lower blood concentrations mean the drug does not work as intended.

The Hyperforin Problem

The active constituent driving CYP3A4 induction in St. John's Wort is hyperforin. Hyperforin activates the pregnane X receptor (PXR), which then upregulates transcription of the CYP3A4 gene. Research published in Clinical Pharmacokinetics established that St. John's Wort preparations standardized to hyperforin content produce clinically meaningful reductions in plasma levels of co-administered CYP3A4 substrates. The magnitude depends on the hyperforin concentration of the specific product, but even low-hyperforin preparations can exert induction effects with daily use.

How Fast Does This Happen?

Enzyme induction is not immediate. CYP3A4 upregulation from St. John's Wort typically builds over 7 to 14 days of consistent daily dosing and persists for a similar period after discontinuation. This means:

• If you started St. John's Wort after your Dayvigo prescription, your sleep medication may have gradually lost effectiveness over the first two weeks without any obvious single event.
• If you stop St. John's Wort today, lemborexant levels will not normalize immediately. Allow 1 to 2 weeks before assuming full effect is restored.

Is This Pharmacokinetic or Pharmacodynamic?

This is a pharmacokinetic interaction. St. John's Wort does not act on orexin receptors or compete with lemborexant at its site of action. It reduces the amount of lemborexant that reaches your brain in the first place. No dose-separation window (taking the two products hours apart) can fix a pharmacokinetic interaction driven by enzyme induction. The enzyme stays elevated around the clock.

What Happens to Your Sleep If You Take Both

The practical result is that your Dayvigo dose becomes functionally lower than prescribed. If you are on lemborexant 5 mg, co-induction by St. John's Wort may reduce your effective exposure enough that you experience little to no benefit. Clinically, this shows up as:

• Returning difficulty falling or staying asleep despite taking your medication as directed
• Feeling as though the drug "stopped working" after a period of effectiveness
• Frustration that leads some women to double their dose without medical guidance, which carries its own risks when the inducer is eventually stopped

The FDA prescribing information for lemborexant does not suggest a dose adjustment to compensate for CYP3A4 induction. The guidance is simply to avoid strong and moderate inducers. There is no approved workaround.

Sex-Specific Pharmacology: Why This Interaction May Hit Women Differently

CYP3A4 Activity Across the Female Life Cycle

Women generally have higher baseline CYP3A4 activity than men, a difference that widens during pregnancy. Estrogen itself can modestly upregulate CYP3A4 expression, which means the degree of additional induction from St. John's Wort may compound differently depending on where you are hormonally. During perimenopause, when estrogen fluctuates widely day to day, baseline CYP3A4 activity is variable. The net effect on lemborexant exposure is harder to predict than in a hormonally stable younger woman.

The Menstrual Cycle and Sleep

Sleep quality varies across the menstrual cycle for many women. The luteal phase, characterized by rising progesterone and then its sharp withdrawal before menstruation, is associated with disrupted REM sleep and increased wakefulness. If you are relying on lemborexant for consistent sleep across your cycle and St. John's Wort is reducing its effectiveness, you will likely notice that luteal-phase sleep is particularly poor, which may be misattributed to hormones alone rather than the drug interaction.

Perimenopause and Postmenopause

This life stage deserves special attention. Perimenopausal and postmenopausal women face sleep disruption from vasomotor symptoms, and many reach for St. John's Wort because older research suggested mild benefit for hot flashes. A Cochrane review of St. John's Wort for menopausal symptoms found insufficient evidence to recommend it for that indication. If you are using it for hot flashes while also taking Dayvigo for sleep, you are accepting a confirmed drug interaction for an unproven benefit. That trade-off deserves a direct conversation with your clinician.

A clinical decision framework for perimenopausal women using both:

1. If St. John's Wort is being used for mild depressive symptoms: evidence-based alternatives include SSRIs (escitalopram, paroxetine, sertraline) and SNRIs, which do not induce CYP3A4. Discuss with your prescriber.
2. If it is being used for hot flashes: low-dose paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal option in that class; fezolinetant (Veozah) is a newer NK3 receptor antagonist that does not interact with lemborexant.
3. If it is being used for sleep: lemborexant itself is your sleep medication. Taking a supplement that undermines it is counterproductive.

Pregnancy, Lactation, and Contraception

Lemborexant in Pregnancy

Lemborexant has not been studied in human pregnancy. Animal reproductive toxicity studies showed embryofetal developmental effects at exposures above therapeutic doses. The drug has no assigned FDA pregnancy category under the post-2015 labeling system, but the prescribing information states that the potential risk to a human fetus is unknown and that treatment during pregnancy is not recommended.

If you are trying to conceive or become pregnant while taking lemborexant, you should discuss stopping the medication with your prescriber before conception if clinically feasible. CBT-I (cognitive behavioral therapy for insomnia) is the preferred first-line treatment for insomnia in pregnancy and carries no fetal risk.

Lemborexant and Breastfeeding

Lemborexant and its active metabolites are present in rat milk. Human lactation data do not exist. Because the drug acts on the central nervous system and infant exposure cannot be excluded, most clinicians advise against using lemborexant while breastfeeding. If postpartum insomnia is severe, discuss safer alternatives with your OB-GYN or a lactation-informed sleep medicine specialist.

St. John's Wort in Pregnancy and Lactation

St. John's Wort is also not recommended in pregnancy or lactation. Limited human data suggest that hyperforin passes into breast milk, and infant colic and sedation have been reported in case series. The safety profile in pregnancy is insufficiently characterized. Neither product should be used casually during these life stages.

Contraception Note

Lemborexant is not itself teratogenic at therapeutic doses in available animal data, but because pregnancy data in humans are absent, reliable contraception is reasonable practice for women of reproductive age who wish to avoid pregnancy while taking it. St. John's Wort is separately documented to reduce the effectiveness of oral contraceptives via the same CYP3A4 induction mechanism, which lowers ethinyl estradiol and progestin plasma levels. This is a critical point: if you are relying on a combined oral contraceptive for pregnancy prevention and you add St. John's Wort, your contraceptive may fail. Use a barrier method as backup, or switch to a contraceptive method not affected by enzyme induction (copper IUD, levonorgestrel IUD, medroxyprogesterone injection).

Who This Is Right For and Who It Is Not

Women Who Should Stop St. John's Wort Immediately

• Anyone currently taking lemborexant 5 mg or 10 mg for insomnia
• Anyone whose Dayvigo "stopped working" after starting an herbal supplement
• Anyone taking oral contraceptives alongside St. John's Wort (separate concern, but equally important)
• Postmenopausal women using SJW for mood or hot flashes while on any CYP3A4-substrate medication

Women for Whom St. John's Wort May Be Appropriate

St. John's Wort has demonstrated modest efficacy for mild to moderate depression in several meta-analyses, and for women who take no CYP3A4-metabolized medications, have no cardiac conditions (it can affect the QTc interval at high doses), and are not pregnant or breastfeeding, it may have a role under medical supervision. The critical prerequisite is a complete medication review by your pharmacist or clinician before starting it.

Women Who Need a Different Sleep Strategy

If you cannot safely take lemborexant (due to cost, interactions, pregnancy) or you want to reduce medication dependence, the following options are supported by evidence:

• CBT-I: Recommended as first-line therapy for chronic insomnia by the American College of Physicians. Digital CBT-I programs (Sleepio, Somryst) are accessible without a prescription.
• Melatonin: Not a CYP3A4 substrate at standard doses. Safe to combine with lemborexant in most cases, though your clinician should be aware.
• Suvorexant (Belsomra): Also a DORA and shares the same CYP3A4 interaction profile with St. John's Wort. Not a safe swap.
• Low-dose doxepin (Silenor 3-6 mg): Metabolized primarily by CYP2D6, not CYP3A4. A potential alternative if CYP3A4 interactions are a recurring concern, though it carries its own side effect profile.

What to Do If You Are Already Taking Both

If you are currently taking both lemborexant and St. John's Wort, take these steps:

1. Do not stop lemborexant abruptly without speaking to your prescriber. Dayvigo is not associated with physical withdrawal the way benzodiazepines are, but your prescriber should know about any changes.
2. Stop the St. John's Wort and allow 2 weeks for enzyme induction to subside before assuming your lemborexant is back to full effect.
3. Tell your pharmacist about every supplement you take. Many community pharmacies have interaction-checking software that flags CYP3A4 inducers, but they can only catch it if they know what you are taking.
4. Ask for a full medication review if you take three or more prescription medications or supplements, particularly if you are perimenopausal or postmenopausal and managing multiple symptoms with a combination of prescription drugs and OTC supplements.

A 2017 survey published in JAMA Internal Medicine found that more than 34% of adults using prescription medications also used dietary supplements, and fewer than half disclosed supplement use to their prescribing clinician. Women were more likely to use supplements than men. The disclosure gap is not a minor administrative issue. It is where drug-supplement interactions happen.

Monitoring and Follow-Up

No laboratory test can directly measure lemborexant effectiveness in clinical practice. Monitoring is clinical: ask yourself whether your sleep has changed since starting or stopping St. John's Wort. Your prescriber may use validated tools like the Insomnia Severity Index (ISI) at follow-up visits. A score increase (worsening insomnia) while on a stable lemborexant dose should prompt a medication and supplement review.

There are no specific monitoring parameters for CYP3A4 interaction severity with lemborexant in current guidelines beyond clinical assessment. The FDA label guidance is avoidance, not dose titration.

The Evidence Gap in Women

Women were included in the SUNRISE trials, but sex-disaggregated pharmacokinetic data for lemborexant specifically examining CYP3A4 induction interactions by hormonal status are not publicly available. The CYP3A4 induction data for St. John's Wort were largely developed in studies using male subjects or mixed-sex groups without sex-stratified analysis. This is a genuine evidence gap. The recommendation to avoid the combination is based on the mechanism and analog data from other CYP3A4 substrates, not on a dedicated study of lemborexant plus St. John's Wort in women across hormonal life stages. Your clinician should be aware that the guidance is extrapolated from mechanistic principles and class effects, not from a randomized trial in perimenopausal women taking both products.